A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo).

Trial Profile

A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Mar 2009 Actual end date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
    • 26 Jun 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 26 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top